TR200100974T2 - Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi - Google Patents

Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi

Info

Publication number
TR200100974T2
TR200100974T2 TR2001/00974T TR200100974T TR200100974T2 TR 200100974 T2 TR200100974 T2 TR 200100974T2 TR 2001/00974 T TR2001/00974 T TR 2001/00974T TR 200100974 T TR200100974 T TR 200100974T TR 200100974 T2 TR200100974 T2 TR 200100974T2
Authority
TR
Turkey
Prior art keywords
shock
respiratory distress
blocking
systematic
lymphotoxin beta
Prior art date
Application number
TR2001/00974T
Other languages
English (en)
Inventor
Browning Jeff
Pugielli Maryann
Ahmed Rafi
Original Assignee
Biogen, Inc.
Emory Universty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc., Emory Universty filed Critical Biogen, Inc.
Publication of TR200100974T2 publication Critical patent/TR200100974T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bu bulus, bir kisiye, etkili bir miktarda bir LT-B bloke edici madde ve farmasötik açidan kabul edilebilir bir tasiyici tatbik etmek suretiyle, bu kiside antivirütik bir tepki meydana getirmek için yöntemler saglar. Bu bulus özellikle, virüslerin neden oldugu sistemik sok ve solunum zorlugunun tedavi edilmesi için yöntemler saglar.
TR2001/00974T 1998-10-09 1999-10-08 Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi TR200100974T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10366298P 1998-10-09 1998-10-09

Publications (1)

Publication Number Publication Date
TR200100974T2 true TR200100974T2 (tr) 2001-11-21

Family

ID=22296372

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00974T TR200100974T2 (tr) 1998-10-09 1999-10-08 Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi

Country Status (27)

Country Link
US (3) US20020001585A1 (tr)
EP (1) EP1119370B1 (tr)
JP (2) JP4713738B2 (tr)
KR (1) KR100888832B1 (tr)
CN (1) CN1200733C (tr)
AT (1) ATE329618T1 (tr)
AU (1) AU777492C (tr)
BR (1) BR9915025A (tr)
CA (1) CA2344049C (tr)
CY (1) CY1105059T1 (tr)
CZ (1) CZ20011272A3 (tr)
DE (1) DE69931944T2 (tr)
DK (1) DK1119370T3 (tr)
EA (1) EA006703B1 (tr)
EE (1) EE04661B1 (tr)
ES (1) ES2267294T3 (tr)
HU (1) HUP0103773A3 (tr)
IL (2) IL142284A0 (tr)
IS (1) IS2514B (tr)
NO (1) NO326905B1 (tr)
NZ (1) NZ510560A (tr)
PL (1) PL195264B1 (tr)
PT (1) PT1119370E (tr)
SG (1) SG121778A1 (tr)
SK (1) SK4662001A3 (tr)
TR (1) TR200100974T2 (tr)
WO (1) WO2000021558A1 (tr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
DE69931944T2 (de) * 1998-10-09 2007-02-08 Biogen Idec Ma Inc., Cambridge Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
AU5338701A (en) * 2000-04-12 2001-10-30 Jolla Inst Allergy Immunolog Ligand for herpes simplex virus entry mediator and methods of use
JP5091476B2 (ja) * 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
WO2005092927A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
US8067375B2 (en) 2006-10-20 2011-11-29 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor
EP3750554A3 (en) * 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
CN106591446A (zh) * 2016-12-07 2017-04-26 中国人民解放军军事医学科学院微生物流行病研究所 细胞通路调控分子在作为药物靶点及诊断ebov感染中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5795964A (en) * 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
AU8228891A (en) * 1990-06-27 1992-01-23 Biogen, Inc. Surface complexed lymphotoxin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0672143B1 (en) 1992-12-04 2008-06-04 Biogen Idec MA Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
EE04453B1 (et) 1995-01-26 2005-04-15 Biogen, Incorporated Lümfotoksiin-a/ß kompleksid ja antilümfotoksiin-ßretseptori antikehad kasvajavastaste agensitena
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
DE69736244T2 (de) * 1996-10-25 2007-05-31 Biogen Idec Ma Inc., Cambridge Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
DE69931944T2 (de) * 1998-10-09 2007-02-08 Biogen Idec Ma Inc., Cambridge Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
AU2003248782A1 (en) * 2002-07-01 2004-01-19 Biogen Idec Ma Inc. Humanized anti-lymphotoxin beta receptor antibodies

Also Published As

Publication number Publication date
ES2267294T3 (es) 2007-03-01
JP4713738B2 (ja) 2011-06-29
SK4662001A3 (en) 2001-11-06
CN1200733C (zh) 2005-05-11
BR9915025A (pt) 2001-08-14
US20020001585A1 (en) 2002-01-03
SG121778A1 (en) 2006-05-26
PL195264B1 (pl) 2007-08-31
CA2344049C (en) 2009-12-15
WO2000021558A1 (en) 2000-04-20
PT1119370E (pt) 2006-09-29
AU777492C (en) 2005-05-26
NO326905B1 (no) 2009-03-16
DE69931944D1 (de) 2006-07-27
NO20011757L (no) 2001-06-08
AU6296499A (en) 2000-05-01
US7452530B2 (en) 2008-11-18
EE04661B1 (et) 2006-08-15
JP2010155852A (ja) 2010-07-15
NO20011757D0 (no) 2001-04-06
KR100888832B1 (ko) 2009-03-17
IS5882A (is) 2001-03-09
ATE329618T1 (de) 2006-07-15
EP1119370A1 (en) 2001-08-01
CN1323223A (zh) 2001-11-21
HUP0103773A3 (en) 2003-10-28
IS2514B (is) 2009-06-15
DK1119370T3 (da) 2006-10-02
AU777492B2 (en) 2004-10-21
EE200100211A (et) 2002-08-15
KR20010080073A (ko) 2001-08-22
IL142284A0 (en) 2002-03-10
CY1105059T1 (el) 2010-03-03
US20040198635A1 (en) 2004-10-07
IL142284A (en) 2009-11-18
CZ20011272A3 (cs) 2001-09-12
EP1119370B1 (en) 2006-06-14
US20090087403A1 (en) 2009-04-02
EA006703B1 (ru) 2006-02-24
NZ510560A (en) 2003-09-26
DE69931944T2 (de) 2007-02-08
CA2344049A1 (en) 2000-04-20
WO2000021558A9 (en) 2001-05-25
EA200100430A1 (ru) 2001-10-22
HUP0103773A2 (hu) 2002-01-28
PL347177A1 (en) 2002-03-25
JP2002527403A (ja) 2002-08-27

Similar Documents

Publication Publication Date Title
TR200100974T2 (tr) Virütik kaynaklı sistematik şok ve solunum zorluğunun,lenfotoksin beta yolunu bloke etmek suretiyle geri çevrilmesi
TR199903053T2 (tr) Benzimidazol türevleri.
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
DE60219627D1 (de) Nachweis und therapie von empfindlichem plaque mit photodynamischen verbindungen
TR200002761T2 (tr) HIV enfeksiyonlarının tedavisi için üç-ikameli 1,3,5-triazin türevleri.
TR200002355T2 (tr) 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
BR9707233A (pt) Fenantridinas
TR199801930T2 (tr) 6-Fenilpiridil-2-amin türevleri.
PL371736A1 (en) Method for administering glp-1 molecules
TR200102977T2 (tr) Yeni tedavi yöntemi.
DK0889886T5 (da) Hidtil ukendte, i 6-stilling substituerede phenanthridiner
TR200100047T2 (tr) Tiyobenzimidazol türevleri
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
AR002987A1 (es) Composicion farmaceutica para el tratamiento de infecciones virales ocanceres o tumores, composicion de dosis unitaria que la comprende y uso para dicho tratamiento
TR199900951T2 (tr) Gögüs kanserinin engellenmesi için yöntemler.
TR200002801T2 (tr) PDE IV engelleyici piridin türevleri
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
ATE468130T1 (de) Inhibitoren der kostimulation via ox40 und deren verwendung gegen eine von virusen induzierten immunpathologie
DE60135743D1 (de) Liposomale einkapselung von alphastrahlern, und deren verwendung
EP0149475A3 (en) Medicaments for the treatment and prevention of liver damage
TR199801133T2 (tr) Tip II diyabetin tedavisi veya önlenmesi için nitrik oksit (NO) sentaz inhibitörü